Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.
Level 3 - non-randomized controlled study
Systematic review and meta-analysis of observational neuroimaging studies
PubMed 26402632 · doi:10.3233/JAD-143225
What was done
Authors conducted a systematic review and meta-analysis across PubMed, Cochrane Library, Ovid, Embase, and EBSCO to evaluate proton magnetic resonance spectroscopy (1H-MRS) cerebral metabolite alterations in Alzheimer's disease. Using Hedges' g effect sizes, they synthesized data across 38 observational studies investigating brain regions linked to cognitive decline.
What was found
N-acetyl aspartate (NAA) was significantly decreased in Alzheimer's patients in the posterior cingulate (effect size = -0.924, p < 0.005), left hippocampus (effect size = -1.329, p < 0.005), and right hippocampus (effect size = -1.287, p < 0.005). The NAA/creatine ratio was decreased in the posterior cingulate (effect size = -1.052, p < 0.005). The myo-inositol/creatine ratio was significantly elevated in the posterior cingulate and parietal gray matter, though numeric effect sizes were not reported in the abstract. Data were insufficient to assess the efficacy of pharmacological interventions on metabolite levels.
Why it matters
This synthesis demonstrates consistent metabolic alterations in brain regions key to Alzheimer's pathology, supporting 1H-MRS markers like NAA and myo-inositol as candidate non-invasive biomarkers of neurodegeneration.
Limits
The review included only observational studies. Total participant numbers, exact effect sizes for myo-inositol, and between-study heterogeneity metrics are not reported in the abstract. Diagnostic accuracy statistics such as sensitivity and specificity were not determined, and data were insufficient to assess treatment effects.
Cited by
- contradicts Patients with Alzheimer's disease, clinical depression, and concussion have reduced baseline creatine levels in the brain.